Empowering Oncologists: How far can purpose and passion take you in cancer care? / cancer, Empowering Oncologists, Jasmine Kamboj, OncoDaily, Oncology, Toni

Basic science discoveries made by Dana-Farber's William G. Kaelin Jr., MD, and his colleagues are propelling powerful new therapies for kidney cancer.

We're excited to join this incredible initiative! This organization's mission is very important to us and we're proud to help them make a difference. Please support us by giving to our page. Every dol...

Published: February 6, 2025Written by: Beth DoughertyMedically Reviewed By: Atish Choudhury, MD, PhD, Toni Choueiri, MD, and Mark Pomerantz, MDDana-Farber’s genitourinary cancer team is devoted to res...

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful...

Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an inte...

None of the nine patients who received the vaccine after surgery experienced recurrence over three years.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

A phase I clinical trial supports the safety and feasibility of a vaccine to limit disease recurrence in people with kidney cancer.

A phase I clinical trial supports the safety and feasibility of a vaccine to limit disease recurrence in people with kidney cancer.

All nine patients treated at Dana-Farber Cancer Institute in a phase 1 trial of a personalized cancer vaccine for patients with stage III or IV kidney cancer with a high risk of recurrence, generated ...

Natural killer (NK) cells are important contributors to antitumor immunity in clear-cell renal cell carcinoma (ccRCC). However, their phenotype, funct…

Resources for patients with cancer and care providers impacted by natural disasters and other catastrophic events.

Dr. Ravi Salgia is an oncologist at City of Hope cancer center. When he and his wife and adult daughter were evacuated from their Pasadena home due to the fires, they followed him to the hospital to h...

The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine and much more.

Top 5 Prostate Cancer Trials of 2024 by Toni Choueiri / AACR, ARANOTE trial, cancer, Mark Pomerantz, OncoDaily, Oncology, prostate cancer, Toni Choueiri